Pathologist · Royal Marsden · United Kingdom (GB) · Oncology
Data minimisation
Cadence target for Tier 3: 1 per year (assumption)
2 of 1 expected engagements
No insights captured from engagements with this stakeholder.
All engagements including drafts, newest first
| Date | Type | Format | MSL | Product | Topics | Insights | Flags | Status | |
|---|---|---|---|---|---|---|---|---|---|
| 07 Sept 2026 | Payer / HTA meeting | In person | James Whitfield | Vantrexa | Elderly / ECOG 2 patientsComparator checkpoint monotherapy+1 | 0 | — | Reviewed | ENG-0050 |
| 04 May 2026 | Medical education | Phone | James Whitfield | Vantrexa | Brain-metastasis subgroup dataSequencing after progression | 0 | — | Reviewed | ENG-0031 |
07 Sept 2026
Elderly / ECOG 2 patients, Comparator checkpoint monotherapy, Chemotherapy-free first line
04 May 2026
Brain-metastasis subgroup data, Sequencing after progression
Royal Marsden
Thoracic medical oncologist
Radiation oncologist
Community nephrologist
Community nephrologist
Renal pathologist
Headache specialist
Primary care physician